FDA Inspection 1147393 — Labcorp Drug Development
The FDA completed an inspection of Labcorp Drug Development on June 17, 2021 in Princeton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 17, 2021
- Fiscal Year
- 2021
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Princeton, NJ (United States)
Additional Details
Sponsor, Contract Research Organization